{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:06:30Z","timestamp":1791378390079,"version":"4.3.2"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.radonc.2020.05.033","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T21:23:14Z","timestamp":1590009794000},"page":"222-227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Can we safely reduce the radiation dose to the heart while compromising the dose to the lungs in oesophageal cancer patients?"],"prefix":"10.1016","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1648-6813","authenticated-orcid":false,"given":"Jannet C.","family":"Beukema","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6644-274X","authenticated-orcid":false,"given":"Nanna M.","family":"Sijtsema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Tian","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes A.","family":"Langendijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisanne V.","family":"van Dijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"van Luijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruki","family":"Teshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina T.","family":"Muijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2020.05.033_b0005","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2020.05.033_b0010","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S1470-2045(11)70142-5","article-title":"Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis","volume":"12","author":"Sjoquist","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2020.05.033_b0015","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1200\/JCO.2016.69.8480","article-title":"Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures","volume":"35","author":"Van Den Bogaard","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2020.05.033_b0020","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2020.05.033_b0025","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.radonc.2014.11.037","article-title":"Is cardiac toxicity a relevant issue in the radiation treatment of esophageal cancer?","volume":"114","author":"Beukema","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.05.033_b0030","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s00066-017-1127-8","article-title":"Dosimetric predictors of radiation-induced pericardial effusion in esophageal cancer","volume":"193","author":"Ogino","year":"2017","journal-title":"Strahlentherapie Und Onkol"},{"key":"10.1016\/j.radonc.2020.05.033_b0035","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00066-016-0956-1","article-title":"Symptomatic radiation-induced cardiac disease in long-term survivors of esophageal cancer","author":"Ogino","year":"2016","journal-title":"Strahlentherapie Und Onkol"},{"key":"10.1016\/j.radonc.2020.05.033_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13014-014-0310-7","article-title":"Effects on heart function of neoadjuvant chemotherapy and chemoradiotherapy in patients with cancer in the esophagus or gastroesophageal junction \u2013 a prospective cohort pilot study within a randomized clinical trial","volume":"10","author":"Lund","year":"2015","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2020.05.033_b0045","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.crad.2014.08.010","article-title":"MRI fi ndings of radiation-induced myocardial damage in patients with oesophageal cancer","volume":"69","author":"Umezawa","year":"2014","journal-title":"Clin Radiol"},{"key":"10.1016\/j.radonc.2020.05.033_b0050","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","article-title":"Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial p","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2020.05.033_b0055","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jtho.2016.09.134","article-title":"Heart dose is an independent dosimetric predictor of overall survival in locally advanced non-small cell lung cancer","volume":"12","author":"Speirs","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2020.05.033_b0060","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/cncr.29857","article-title":"Radiation modality use and cardiopulmonary mortality risk in elderly patients with esophageal cancer","volume":"122","author":"Lin","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2020.05.033_b0065","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.radonc.2017.04.017","article-title":"Dose to heart substructures is associated with non-cancer death after SBRT in stage I-II NSCLC patients","volume":"123","author":"Stam","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.05.033_b0070","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1016\/j.jacc.2019.03.500","article-title":"Cardiac radiation dose, cardiac disease, and mortality in patients with lung cancer","volume":"73","author":"Atkins","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.radonc.2020.05.033_b0075","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ijrobp.2017.04.026","article-title":"The impact of cardiac radiation dosimetry on survival after radiation therapy for non-small cell lung cancer","volume":"99","author":"Vivekanandan","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.05.033_b0080","first-page":"17","article-title":"Clinical and Translational Radiation Oncology Heart and lung doses are independent predictors of overall survival in esophageal cancer after chemoradiotherapy","volume":"17","author":"Xu","year":"2019","journal-title":"Clin Transl Radiat Oncol"},{"issue":"7","key":"10.1016\/j.radonc.2020.05.033_b0085","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1245\/s10434-010-1024-1","article-title":"Editorial: 7th edition of the AJCC cancer staging manual: Esophagus and esophagogastric junction","volume":"17","author":"Rice","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.radonc.2020.05.033_b0090","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijrobp.2009.10.058","article-title":"Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer","volume":"79","author":"Feng","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.05.033_b0095","doi-asserted-by":"crossref","first-page":"W1","DOI":"10.7326\/M14-0698","article-title":"Transparent Reporting of a multivariable prediction model for Individual Prognosis or Disagnosis (TRIPOD): explanation and elaboration","volume":"162","author":"Moons","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.radonc.2020.05.033_b0100","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/00130404-200211000-00009","article-title":"Effect of concurrent radiation therapy and chemotherapy on pulmonary function in patients with esophageal cancer: dose-volume histogram analysis","volume":"8","author":"Gergel","year":"2002","journal-title":"Cancer J"},{"key":"10.1016\/j.radonc.2020.05.033_b0105","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.radonc.2010.02.006","article-title":"Analysis of dose-volume histogram parameters for radiation pneumonitis after definitive concurrent chemoradiotherapy for esophageal cancer","volume":"95","author":"Asakura","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.05.033_b0110","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20140168","article-title":"Predictive factors for pericardial effusion identified by heart dose-volume histogram analysis in oesophageal cancer patients treated with chemoradiotherapy","volume":"88","author":"Hayashi","year":"2015","journal-title":"Br J Radiol"},{"key":"10.1016\/j.radonc.2020.05.033_b0115","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ijrobp.2007.10.056","article-title":"Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy","volume":"70","author":"Wei","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.05.033_b0120","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0140-6736(98)06341-7","article-title":"Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group","volume":"352","author":"\u201cPort Meta-analysis Trialists group\u201d","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2020.05.033_b0125","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.ijrobp.2012.02.015","article-title":"Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer","volume":"84","author":"Lin","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.05.033_b0130","first-page":"516","article-title":"Increased risk of death due to heart disease after radiotherapy for esophageal cancer","volume":"6","author":"Frandsen","year":"2015","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.radonc.2020.05.033_b0135","doi-asserted-by":"crossref","unstructured":"Gharzai L, Verma V, Denniston KA, Bhirud AR, Bennion NR, Lin C. Radiation therapy and cardiac death in long-term survivors of esophageal cancer: An analysis of the surveillance, epidemiology, and end result database. PLoS One 2016;11. https:\/\/doi.org\/10.1371\/journal.pone.0158916.","DOI":"10.1371\/journal.pone.0158916"},{"key":"10.1016\/j.radonc.2020.05.033_b0140","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.radonc.2016.04.025","article-title":"Impact of heart and lung dose on early survival in patients with non-small cell lung cancer treated with chemoradiation","volume":"119","author":"Tucker","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.05.033_b0145","first-page":"1","article-title":"Prognostic significance of lung radiation dose in patients with esophageal cancer treated with neoadjuvant chemoradiotherapy","volume":"14","author":"Bin","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2020.05.033_b0150","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.radonc.2019.09.015","article-title":"NTCP model for postoperative complications and one-year mortality after trimodality treatment in oesophageal cancer","volume":"141","author":"Thomas","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.05.033_b0155","article-title":"Randomized phase IIB trial of proton beam therapy versus intensity-modulated radiation therapy for locally advanced esophageal cancer","volume":"38","author":"Lin","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2020.05.033_b0160","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.radonc.2012.05.008","article-title":"Biological mechanisms of normal tissue damage: importance for the design of NTCP models","volume":"105","author":"Trott","year":"2012","journal-title":"Radiother Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814020302899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814020302899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:12:13Z","timestamp":1759122733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814020302899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":32,"alternative-id":["S0167814020302899"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2020.05.033","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can we safely reduce the radiation dose to the heart while compromising the dose to the lungs in oesophageal cancer patients?","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2020.05.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}